Opinion of the Transparency Council – sirolimusum
At its meeting on 10 March 2025, the Transparency Council adopted opinion No. 41/2025 on the reimbursement of medicinal products containing the active substance sirolimusum for an indication, dosage or method of administration other than that specified in the Summary of Product Characteristics, i.e. Klippel-Trénaunay-Syndrome